Welcome to Aker BioMarine's Q2 presentation. We'll start with me giving some comments to the report that we published today. Katrine here will take you through the financials of the quarter, and then I'm going to take you through the outlook and the recent company development, and also give some more deeper insight into the Superba segment and also the performance in harvesting. Then we're going to have a Q&A at the end. You can through this Teams application, put in questions. You can already start to do that now, and then we will answer those questions at the end of the session today. With that, I'm going to start with taking you through the key comments to the report today.
First of all, I'm happy to report that we are back into growth for Aker BioMarine, both versus the first quarter, but also compared to the same quarter a year ago. There are several areas that are developing very positively. The brand segment is developing really strongly. The QRILL segment is developing really strongly and also continue to surprise us positively. We also have some challenges. The Superba situation that we talked about before, it's still here now in Q2, and also we have challenges in the harvesting area. We'll go more into details of this in the presentation here now. There's been some key events throughout the quarter.
The first one is that we now are listed on the Oslo Stock Exchange main list, which gives us access to a broader set of investors and should be good in general for all the investors. Also, we have hired Doug Hicks to lead our venture into the pharmaceutical space. As you know, we started with our Lysoveta product to start to make the first move into the pharmaceutical area. This is a strategic area for Aker BioMarine, and we are happy to have now Doug Hicks, which has a long track record in the pharmaceutical space on board to lead us through that development. Also on the innovation side with INVI Protein, we in the quarter achieved regulatory approval for the product in the U.S., which means it's now allowed to sell and market in the U.S. market, which is a key milestone for the development there.
We have now ordered what we call a drone, UVS, which basically is a 7- 10-meter-long vessel autonomously, that can travel two -three weeks alone to collect data and search for krill and will help us digitalize our offshore operation and help us find the krill and make sure that we are at the right spots at the right time. That will be very important for the efficiency of our offshore operation and also make sure that our carbon footprint is being reduced. Katrine will take you through the details of the financials, but as you can see, almost 50% growth from last quarter, 3% growth versus the same quarter last year, and about 10% growth quarter-over-quarter on EBITDA. It's worth remembering that in 2020, we adjusted out the marketing costs related to Kori. This year, we are not doing that.
We go through the P&L and therefore also negatively impacting the EBITDA. The underlying EBITDA development is stronger than the 10% that we're actually showing here. I'm going to take you through and start with the ingredients segment. As mentioned, we've been having challenging with harvesting in the second quarter. We had a fairly good first quarter where we harvested in the south part of the Antarctic Ocean. Once that area closed and we moved further north, the availability of krill was lower. The vessel has so far this season worked perfectly, fully operational, no technical issues. It's just the fact that krill is not in the areas where we are harvesting. I think also I would like to mention that there have been recent surveys of the krill biomass that indicates a positive development and healthy biomass stock of krill in Antarctica.
There's no worries related to if this krill is there or not, but just this year it has not been in the area where we fish. Antarctic Provider, our supply vessel has been ramping up as planned. Been working really well and are now into fully operation, which means that our previous vessel, La Manche, and the vessel we have leased, Trinitas, will now be dismissed, and Provider will be our only vessel to support our fishing vessels in Antarctica, not only important for efficiency but also cost. We have also written in the report that during an offload, we got COVID on board Provider, our support vessel. We were able to contain it. We follow strict procedures, so putting crew into isolation, and making sure that we didn't have a spread on board our fishing vessels.
As a precautionary limit, we also put all the key crew that came from Provider on board the fishing vessel also in isolation, which meant that we lost 10-14 days of fishing because we had to kind of keep everybody in their cabins. We managed it out. There is no outbreak, it's now finished. It's just a good reminder that COVID is still around and something that we have to deal with going forward as well. On the onshore side, Houston continue to be a very positive story.
As I mentioned before, when it comes to the impact on margins, our performance in Houston impacts just as much as our harvesting operation in Antarctica. Houston continue to develop very positively. Both on volume side and the output coming out of the factory, but also on cost, taking down the unit cost and improving the margins in the Superba segment. On the sales side, Superba continued to be the struggle driven mainly by the situation in South Korea that we have talked about in previous quarters. Still, Korea is now about half of what it was at peak, and as mentioned in the previous quarter, we don't expect and don't plan for that to come back into the previous high levels. Still important to note that Korea is one of the largest markets per capita for krill oil already today at the level we are selling in Korea today.
We also have some challenges in what we call the non-mass market in the U.S., which basically is everything else other than the big retail chains, and where we have seen quite choppy development, and we have identified quite big opportunities in that area that we are now working to close up. We have also gotten halal certification of our product, which is an important milestone for us to offer krill to the Muslim consumers all around the world. On QRILL Aqua, I will give a little bit more deep dive into Superba segment a little bit later. On the krill segments, things have been developing very positively in the quarter. Both the salmon market, especially in Norway and Northern Europe, has been developing very strongly together with the increased salmon prices.
We also have expanded into new customers and new markets in Asia, putting us now in a very good and solid position to capitalize further growth and value in the period to come. June was an all-time high for krill segment. We have never sold as much in one month as we did in June. I think it's also worth mentioning that the pet segment continued to develop very positively, and we see good traction now in both U.S. and Asia, which are relatively new markets for the pet products. Talking about the brand segments, which is one of the key highlights on the positive side from this quarter, we have seen very strong growth in the branded segment, 32% year-over-year growth, driven basically by all category, but especially krill.
40% growth year-over-year of sales of krill products through our brand activities versus the same quarter last year. We see a general growth in all the channels. I think this is a combination of a strong position we have in the products, a good innovation pipeline that coming online these days with the retailers, combined with a normalization after the COVID that drives consumers back into stores. Kori also continues to develop positively with growth versus last quarter, also with new retailers coming on board. Especially happy to announce that Sam's Club has now decided to put Kori on the shelf on the physical stores after running a test on their online shop since last year. Sam's Club is probably the second-largest channel for sale of krill products in the U.S. market. That's really an important milestone for Kori.
Aker BioMarine is now also working on line extension, looking at new innovative krill-based products that can come next to the existing products on the shelf, and that will be presented to the retailers after the summer. Here you can see the development. As you can see, continue to grow the total sales in Q2 increasing the marketing activity somewhat. We're still working to optimize to make sure that we maximize the ROI on marketing dollars. We see continuous improvement there as we also start to scale up the volumes of marketing. This is an ongoing effort to scale up and make sure the ROI, return on investment, is positive on all the marketing activities that we are doing. With that, I'm going to give the word to Katrine, who will take you through the financials.
Yes, good morning. Second quarter has been a good quarter. As Matts said, we are 3% up from Q2 last year and significantly up from Q1 this year with a 48% increase in sales. Also, as Matts have already mentioned, it's the QRILL Aqua in the ingredient segment and the private label from Lang in the brand segment driving the sales growth year-over-year. EBITDA is $19.4 million, up from $17.6 same period last year. Improvement is mainly driven by offshore and onshore operations, where unit costs are down as a result of stronger performance. The gross margin for the group as a whole is up from 36%- 40%, with corresponding improved EBITDA margin at 26%, up from 24% same period last year.
Net debt is down as a result of the capital increase that was completed in connection with the IPO last summer, resulting in net debt of $311 million and an equity ratio of 48%. Moving over to the ingredients segment. The ingredient sales are down 11% from second quarter last year. There is a significant shift in revenue distribution between Superba and krill being 50/50 last quarter, while Superba now is down to 36% and krill up to 64% this quarter. There has been strong growth in the krill category with 17% year-over-year, including all aqua and pet products. We have seen good development in the salmon market, which is important for European sales, and new contracts with large Asian customers that have been activated.
Superba decreased 36% year-over-year, mainly driven by the South Korean situation that Matts has already mentioned, but also due to the company not being successful in capturing recent growth opportunities in the non-mass U.S. market. Strong EBITDA improvement from last quarter as good harvesting in Q1 combined with strong Houston performance improves the gross margins for both Aqua and Superba. Gross margins for the ingredient segment is up 46% from 41% last year, leading to EBITDA margins of 40% up from 32% second quarter last year. Finally, as a one-off, La Manche now moving out of our books. We have accelerated the depreciation profile to match the net sales proceeds, this will have a short-term positive EBITDA effect that is netted out over time as the increased depreciation is then headed into the costs. Moving over to production volumes.
The top graph shows our total onshore oil production of finished goods, including Houston and some smaller third-party production in New Zealand. The Houston output shows a 29% increase over Q2 last year. This is due to the ongoing capacity project 2000 by 2022, which is already yielding both higher volume outputs but also lower operational costs, which is driving down the unit cost and improving the Superba oil margins. The bottom graph shows our offshore meat production, with second quarter volumes being 13,920 tons, down from 16,387 tons same period last year. We have struggled with locating the krill over the past few months, and as a result, not seeing the volumes that we were expecting despite having a technically well-performing fleet. The COVID-19 outbreak on Provider had smaller operational and financial implications.
As already mentioned, La Manche will sail to Turkey in August to undergo ship dismantling and will be replaced by the Antarctic Provider. Moving over to the brands segment. We saw strong revenue growth in the brand segment year-over-year of 32%, driven by private label sales in Lang, showing good post-COVID recovery. Krill being also one of the private label categories with the highest growth in the quarter, 40% year-over-year for Lang. Kori also shows good developments and is growing POS numbers each quarter but still from a low base. Moving over to margins. Gross margins for the brand segment is slightly down from 27% - 25%. This is mainly driven by product and customer mix in the Lang portfolio.
EBITDA margins for brands is down to 2% in the quarter as a result of the Kori marketing cost no longer being adjusted out of the EBITDA, hence driving cost up in the brand segment. We still view this cost as an investment into building the brand, but according to our accounting policy, we cannot adjust for it after the initial launch year. The blue line and the white stack is to illustrate the EBITDA development had the Kori cost been adjusted out also in 2021. As a result of this, EBITDA margin for Aker BioMarine is negative, while Lang had a 14% EBITDA margin, which is stable compared to the same period last year. With the main figures presented, I'll just draw your attention to a few technicalities in the P&L statement.
On the depreciation and amortization line, we have done a small impairment on the customer and trademark portfolio as a result of the lower Superba sales of $1.8 million in the quarter. Secondly, our fuel options are moved from being a financial item down into the other comprehensive income as we're now doing hedge accounting. This can be seen in net financial item line. Finally, the accelerated depreciation profile for La Manche can be seen in the EBITDA reconciliation table where you see a slight increase in the depreciation and amortization line for production assets. This is also, of course, including Antarctic Provider when compared with last year. A few items on the balance sheet. We had total assets of $769 million, up from $678 million, driven by three main topics. Inclusion of Antarctic Provider, derivative assets from our fuel options, and inventory build-up.
The first Antarctic Provider was delivered in February 2021, increasing both our property, plant, and equipment and our debt. Second, the derivative assets reflect the mark-to-market value of our fuel options and is currently at $13.6 million, showing a very strong in-the-money option portfolio. Finally, inventory build-up is a result of a strong Houston production combined with lower Superba sales. Net debt is at $311 million, down from the same period last year, and equity ratio at 48%. Finally, a few comments on cash flow developments. We have a negative cash flow from operations in the quarter due to a negative change in working capital as a result of the inventory build-up of krill oil, as well as sales coming in late in the quarter, building up customer receivables. The change from last period in cash flow from investing activities is explained by the sale of Juvel in May last year.
The change from last period in cash flow from financing activities is driven by a $30 million draw under the RCF in the quarter to fund CapEx related to Houston, Lysoveta and the protein launch plans. This leaves us with a net change in cash for the quarter of -$1.6 million. That concludes the finance section, and I will hand it over back to Matts to go through the outlook.
Thank you, Katrine. I will start with just sharing my reflections from developments over the last 12 months. We had some areas that showed really good progress, and then we had some other areas where we had setbacks. Starting on the good progress, as talked about already today, in the QRILL Aqua segment, things have been developing really positively over the last 12 months. Despite all the challenges coming with COVID, with the low prices for both salmon and shrimp in the market, we've been able to expand both our customer base and our volumes throughout the global market for these types of products. We are now in a very strong position where we have products into all the key markets with the key customers globally and are ready to create value and drive volumes now as things start to normalize.
We see a very positive development through the krill category. We have done some important innovation launches. In the protein, which will be a new segment for Aker BioMarine, just like the krill segment and the Superba segment. We have launched a product, we have gotten approval in the U.S., and we're starting to build a factory here in Norway these days. This will be a big driver of growth long-term for the company, but it will not short-term impact the profitability of our company. It's still a very important value driver that's happened over the last 12 months. With Lysoveta, it's similar. It represents a market in the dietary supplement area with a bigger addressable market than the Omega-3 market we are addressing today with Superba. That will also become a new segment side by side with krill and Superba.
In addition, Lysoveta gives us the entry point into the pharmaceutical area. As you know, we have the first pharmaceutical agreements already signed up, and this is a focus area for Doug Hicks that I presented a little bit earlier, to develop that business together with key partners in this area. It's the same here that the majority of the impact on profits from this product will come later in the planning period and will therefore not have a short-term impact on the profitability of the company. It represents big values and will become a major segment long-term for the company. We have also created and launched AION. AION is developing really positively, scaling up according to plan, and therefore now we are planning for the spin-out of that company.
Even if it will be spinned out shorter, we will also then provide shareholder value to the Aker BioMarine shareholders as part of that spin-out. As soon as we have everything ready related to that, we will inform the market. On the innovation side, we have done a lot of things the last 12 months, and we have now common new business areas that will be important growth engines for the company going forward. Houston continued to perform really well and has done so over a long period of time, giving us, first of all, ability to get more capacity out of the existing CapEx that we have there, limiting the need for further investments in capacity. Number two, it drives the unit cost down and improves the margins for our Superba business, which is a big chunk of what we have today.
All the Lysoveta products will also be produced in the Houston factory. We talked about the brand segment earlier, and you have seen the positive development with an all-time high quarter now in Q2. We see a really good development in the brand area, both with having successful innovations coming on the shelf, driving growth, but also that the existing products we have on the shelf is also growing quite healthy. We have a robust position with strong growth now in the brand segment. Related to Kori, I think it's also important to reflect that launching Kori in the middle of COVID was not the kind of optimal timing to launch a new brand, but nevertheless, it was important for us to do so. We have had a successful launch.
Here comes Aker BioMarine out of nowhere, and already after a year, we are on the shelves on all the major retail chains in the U.S. and have all evaluated the sales performance of Kori the first year, and they all have decided to continue having Kori on the shelf going forward. We also see more and more retailers adopting Kori onto the shelves, demonstrating that it's doing quite well. This provides big value for the company, first of all, in terms of having the platform to continue to develop Kori, but also the possibility for Aker BioMarine to develop new brands and new products on the basis of that platform. Over the last 12 months, a lot of good positive development for the company, some with shorter impact, some with more longer-term impact for the company. We had some setbacks as well.
We talked about the South Korean situation and how that's impacting the overall Superba growth. I will take you through a little deep dive to show you a little bit more insights into the development in Superba. We have had two years now with lower than expected harvesting. Also here, I will take you through some more details. Starting to show you a little bit more of the development of Superba. What you see here, on the left side, is the sales in different regions, and I'm going to take you through each of them. We're looking here at full year basis, and you see Q2, it's last 12 months, so Q2 and then 12 months backward, and then the green one, it's what we expect for 2021. If you say starting on the top, with the gray one, that's Korea.
You can see how that came in in 2019, kind of suddenly with the strong sales in 2019 and 2020. Then you can see about half of the sales now, when you look at the last 12 months. Korea's situation as we have communicated, we are not expecting it to get back into 2019 and 2020 levels. You should rest assured that we are working really hard to try to make that happen. We're working on getting new health claims that allows us to have new marketing claims in the Korean market and working very closely with partners in the Korean market. We have in no way given up to get it back, but where we stand right now, we are not planning for that to come back to the previous levels, but rather stabilizing at the current level where it's at right now.
If you continue down on the, let's call it the bright blue color, which is the next one, that's non-mass market, in the U.S. Meaning that all the channels, which is not the big retail chains, which is below. That's e-commerce players, it's MLM, it's catalog companies, it's companies selling through practitioners, all types of channels where they are selling supplements in the U.S. market. If you look at the history over the last years, you see quite choppy development. Underlying growth, let's say over the last four or five years, but you see especially in 2020 was a spike up. Looking at the last 12 months, you see that's coming down. I think that spike in 2020, it's partly driven by also the Korean situation as some of, especially the e-commerce players in the U.S., position their products towards Korean consumers.
I think also the development that we have seen in 2021 shows that we haven't captured all opportunities that emerged through the growth in e-commerce, after or through COVID. Currently we are going through a strategic process for the U.S. market, and we're also structuring the sales marketing organization to make sure that we can capture all those opportunities that is there in the non-mass market in the U.S., so we can get this back into growth territory as well. Looking at the light blue, this is the mass market in the U.S. This is where Kori plays, and this is where private label plays. As you can see over the last years, in the earlier stages here, you see a decline and that's driven by MegaRed, which has been the leading brand for krill oil mass market in the U.S.
Hasn't succeeded on being that locomotive and that kind of flare light, in the category to drive it in the right direction. This was the background for why we launched Kori. We wanted to take responsibility ourselves to be that locomotive in the market, be that flare light that can show the direction and drive the consumers into the krill category. As you can see now, partially on the last 12 months, but maybe more if you look to the right, you can see year to date, and you see the share of U.S. mass market. You can see that Kori is starting to have a real effect on sales, both on private label and the brands themselves, in the mass market.
We feel that, going forward, the mass market now in good shape, and we have a strategy that works in terms of making sure we have growth in that area going forward. The bottom part, the dark blue, it's everything else, which means Europe, Asia, Pacific, and South America. That's been developing very healthy all along. You can see also to the right, if you look at just the year to date, you see rest of the world, which basically means emerging markets growing really strongly. We have seen what's possible to do in some of the Asian markets through what happened in Korea, and we're now strengthening the sales marketing organization in Asia to go after all the opportunities in the Asian markets like the one we saw in Korea to accelerate the growth in that area.
Also looking at the 2021 plan, the green column there, you see that we are expecting higher sales in the second half for Superba than what we have in the first half. What this has done, this situation mainly then driven by the Korean situation and somewhat driven by the non-mass market in the U.S., is that we have lost a growth opportunity or a growth situation in 2021. The way we see it now, we expect to continue growing now going forward according to the original plans that we had also 12 months ago.
That kind of lost growth that we have had the last year, we do see less likely that we will be able to catch up. Superba is still competing in an attractive market, global Omega-3 market that is in growth, with a clear value proposition, and with customers that are driving activities, driving consumers into the category. We are still good positioned with Superba, but it's going to be harder to catch up the shortfall from 2021. Like I mentioned, we are doing initiatives and improvements to ensure that we get that growth going forward, both from a strategy point of view, but also in the organization to make sure we have a strengthened organization to capture all the opportunities that we know is out there. That was some details on the Superba area. Talking about the harvesting area.
We have now two seasons with lower than expected harvesting. What you see on the left side here on the graph is the daily production per vessel. What we use here, an example is the Antarctic Sea, which is kind of the larger vessel we have where we have a history going back. As you can see since 2014, every year the vessel's been harvesting and performing better and better, driven by investments that we do each shipyard, improvements that will improve the capacity of the vessel, but also driven by the very skilled crew members we have on board the boats that constantly are looking at how we can improve the way we do things to get more production out of the assets we have. You see those two outliers in 2020 and 2021 with a kind of significant drop.
Those drops are driven by different things. As you know, in 2021, it was mainly driven by technical issues. We were struggling with the vessels that had challenging to operate, and that impacted our ability to harvest and produce. This year, all the vessels are operating perfectly. No technical issues. The trawl is in the water, everything is operating, but the krill is not in the area where we are fishing. As I mentioned earlier, the krill biomass is healthy. The last survey that was done where they systematically map the biomass krill in the Antarctica showed a 17% growth of the biomass between year 2000 and 2019. There's no kind of long-term worry that now suddenly the krill is gone.
There is natural variation in the fishery, and unfortunately this season the krill has not been in the area where we have been with our vessels. We are doing initiatives, as I talked about earlier. We have ordered this, let's call it a drone, this unmanned surface vehicle that we will use to collect data and search for krill. This can go three weeks alone and instead of taking our fishing vessels out of fishery, that will go out and look and find where the krill is and then the vessel can follow. It will also collect systematically data that we will use in our predictive models that we already have implemented on our vessels. As you can see, also looking in the forecast forward, we don't expect this low harvest that we have seen now two years in a row in the future.
I think also it has taught us that there will be natural variation in a fishery also going forward. The outlook for 2021. The kind of key change for the 2021 outlook is offshore production and harvesting. We are now guiding at offshore production of between 45,000 and 50,000 tons, down from 60,000-70,000 tons based on the challenges that I just talked about. We expect as long as the equipment is working that the krill will come back. For this year, we have already lost a lot of harvesting opportunities from the first half of this year. Onshore production, we were planning strong and positive development in Houston and we see that's going to continue. There's no change in outlook for our Houston production.
Given the situation in Superba, we have slightly adjusted our revenue growth profile to now what we call modest revenue growth compared to what we call somewhat lower growth in 2021 versus 2020. Nevertheless, despite all the challenges that we have, we're still expecting growth in 2021 versus 2020. Still, the seasonality of our business, both on the revenue side and on the margin side, tells us that the second half will be stronger than the first half. This is the same as we have guided earlier, driven by seasonality, in especially the aquaculture segment, and it's driven by also the seasonality on the unit cost, especially offshore.
Driven by the reduced harvesting numbers, this will impact the margin, especially in the QRILL segment, and therefore we no longer expect an improvement over the EBITDA margin year-over-year, but rather somewhat lower compared to last year. I would like to mention that the underlying EBITDA margin for Aker BioMarine is expected to be higher in 2021 versus 2020. When I say that means when we take out the impact of Kori, where we last year adjusted it out, while we are not doing it this year and just look at the underlying business for ingredient and brand, EBITDA margin is improving again despite the challenges that we are facing this year. On the more medium-term outlook. I think it is important to say that we expect very strong sales earning growth in the coming years. We are positioned well with our products.
We are a leader in our segments. The segments that we are competing or operating are developing very positively. We have still a very strong sales and earning growth projected for the years to come. However, based on what we have seen now on the variability on the harvesting side, the step-up in South Korea that we believe it's hard to catch up, we expect a somewhat later realization of our 2024 aspiration of $200 million EBITDA , but still expecting really strong growth in the years to come. We're working now on an improvement agenda for our company, working on full potential plans in the different areas where we operate. We would like to invite to a capital market update later in the year. We will take you through a deeper look into our different segments, including our strategies and plans going forward.
An invitation to that will follow later. With that, we will move into the Q&A session.
Okay, I will read out the questions. Hi. Your new harvest guiding implies a very modest growth during second quarter 2021 compared to last year, impacted by several challenges. Can you please help us understand why?
Should I answer that?
Yeah, you can take that one.
I think this is on the back of the challenges that we have seen so far this season. We know that things can quickly change in the harvesting side. We are moving in big areas. But based on the history of the first half, it's not prudent to plan with a large comeback the second year, and therefore we have taken down the expectations also for the second half.
Okay, next question. In light of your disappointing Superba sales, will you continue with the capacity expansion in Houston or will you first need to see higher sales in order to avoid further inventory build? I can probably answer that one. I think for this year, we are very comfortable with the output from Houston and it basically meets our strategy of building a much more solid and robust safety stock, having product in our inventory to avoid air freight and also serve customers globally. The point going forward, this will be an important topic and we are also working on initiatives to make sure that we can run Houston on full production capacity while making sure that there are outlets for the products in the market. Next question.
How is it possible to list Aker BioMarine last year on the estimates given and not deliver one single time on all quarters? This is management responsibility and how do you see your own responsibility on this?
Yeah, maybe I can comment on that. I think like I went through at the end, there's been positive and there's been negative developments since we started the IPO. Some things are under our control, some things are not under our control. We still have strong growth agenda in front of us. We have developed a solid platform for that growth going forward. I think also if you look at some of the areas that we have reported over the last quarters, we also have quite some positive surprises and developments. It's not all back, but we see clearly that on the harvesting side and the Superba side, we have not delivered as expected and therefore also we are implementing different initiatives to deal with that.
Next one. Can you say anything about your inventory position in terms of volumes, both in terms of krill, Superba, and year-over-year development for both? I mentioned earlier the Superba safety stock as a result of increased Houston performance. I think with krill what we see there is that we constantly have a very comfortable inventory level also for the krill meal. Despite lower harvesting, we are still able to serve the markets and the growing regions. Again, this will vary going forward with the variation in krill, but we work to make sure that we have sufficient inventory for all products. Can you please say something about the fundraising for the pharmaceutical company using Lysoveta?
Yes. I can give a little update on that. That's developing well. There's currently due diligence process going on with several investors and we hope to close that in the near future.
Last question. Based on your experience on the harvesting, how should we think about harvesting volumes for 2021 and 2022? Is it time to adjust your harvesting capacity, i.e. reduce the number of vessels?
Yeah, I can comment on that. I think for 2022, I think I covered some of this already in the presentation, but the most important factor in a fishery is to make sure that you have equipment that is working. You will have some natural variation from Mother Nature, but as long as the equipment is working and you have in troll in the waters, you will over time perform. We expect that also in 2022. We will have years where we will produce fantastically, well above expectations, and we will have years which will be below. We still will utilize the full capacity that we have in the fleet and we expect that the harvesting levels will come back to good levels that we have seen historically.
Good. I think that was the end of the questions unless there are any. Okay, let's see. One more question. Can you please update us on the liquidity position and available RCF? Yes. As I mentioned in the presentation, we've drawn $30 million in the quarter under the RCF in order to fund CapEx investments for the ongoing innovation projects that we are running. We still have sufficient capacity together with the cash and available debt capacity. We have about $77 million left under the RCF. We are comfortable with the headroom that we have.
With that, we close the presentation. Thanking you all for joining us today.